Prosecution Insights
Last updated: September 24, 2026
Application No. 18/874,981

CSF-1R INHIBITORS AND USES THEREOF

Non-Final OA §112
Filed
Dec 13, 2024
Priority
Jun 15, 2022 — CN PCT/CN2022/098943 +2 more
Examiner
ANDERSON, REBECCA L
Art Unit
Tech Center
Assignee
Myrobalan Therapeutics Inc.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
764 granted / 1041 resolved
+13.4% vs TC avg
Strong +24% interview lift
Without
With
+23.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
49 currently pending
Career history
1094
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
18.7%
-21.3% vs TC avg
§102
24.1%
-15.9% vs TC avg
§112
32.9%
-7.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1041 resolved cases

Office Action

§112
DETAILED ACTION Claims 1-3, 7, 13, 17, 19, 23, 26, 27, 39, and 42-50 are currently pending in the instant application. Claims 1-3, 7, 13, 17, 19, 23, 26, 27, 39, and 43-45 and 47-50 are allowable. Claims 42 and 46 are rejected. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Drawings The drawings are objected to because Figure 4A is illegible. Specifically, the numbers and symbols above the bars in the bar graph are illegible and the legend is illegible: PNG media_image1.png 236 400 media_image1.png Greyscale . Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 42 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims must, under modern claim practice, stand alone to define an invention, and incorporation into claims by express reference to the specification is not permitted. Ex parte Fressola, 27 USPQ 2d 1608 (1993). Currently, claim 42 references the specification Table 1. It is suggested that claim 42 be amended to include the compound names and/or structures of the compounds of Table 1 as found in the specification. Claim 46 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 46, the phrases "such as" and “including” renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Closest Art The closest art is Guo et al (Form 892) which provides the compound 3x on page Table 2: PNG media_image2.png 192 380 media_image2.png Greyscale which corresponds to the formula: PNG media_image3.png 180 466 media_image3.png Greyscale differs from the instant claims as Z in the instantly claimed formula (I): PNG media_image4.png 150 282 media_image4.png Greyscale is CH or NH. Additionally, R2, R4 and R5 of X3, X4, and X5 in the instant claims, while including NR*C(O)R*, R* of the instant claims can only be PNG media_image5.png 74 586 media_image5.png Greyscale which does not include phenyl. The compound 3x also does not read on Formula (I’): PNG media_image6.png 146 286 media_image6.png Greyscale of the instant claims (see instant claim 39). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 9 September 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

Dec 13, 2024
Application Filed
Sep 14, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735385
ALKYLSULFENYL THIOCARBONATES: PRECURSORS TO HYDROPERSULFIDES POTENTLY ATTENUATE OXIDATIVE STRESS
2y 10m to grant Granted Sep 15, 2026
Patent 12729196
N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
3y 2m to grant Granted Sep 08, 2026
Patent 12715864
PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE
3y 9m to grant Granted Aug 25, 2026
Patent 12703706
ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE
3y 2m to grant Granted Aug 11, 2026
Patent 12692233
ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE
3y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+23.5%)
2y 4m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1041 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month